ALX Oncology Appoints Barbara Klencke as Interim Chief Medical Officer
PUBLIC · ALXOSep 12, 2025
Position
Chief Medical Officer
Company
ALX Oncology
Barbara Klencke
San FranciscoBiotechnologyHealth CareMedicalTherapeutics
Description
ALX Oncology has appointed Dr Barbara Klencke as Interim Chief Medical Officer following the resignation of Dr. Alan Sandler from the role. Dr Klencke, who has extensive experience in oncology drug development, will transition from her current position on the Board of Directors to lead the company’s medical strategy.
Who to call at ALX Oncology, and when
A new leader at ALX Oncology brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day ALX Oncology raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at ALX Oncology, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
ALX Oncology
Location
San Francisco, California, United States
About
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ALX Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealth CareMedicalTherapeutics